Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Uterine Cervical Neoplasms × Radiotherapy, Adjuvant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Esophageal Neoplasms 2 Uterine Cervical Neoplasms 1 Prostatic Neoplasms 1 Neoplasms 1 Lymphatic Metastasis 1 Laryngeal Neoplasms 1 Laryngeal Diseases 1 Carcinoma, Squamous Cell 1 Breast Cancer Radiotherapy 1

Interventions

Cisplatin 47 Paclitaxel 22 Carboplatin 18 Radiotherapy 16 Brachytherapy 16 Gemcitabine 12 human papillomavirus vaccine, L1 type 16, 18 11 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 11 Topotecan 8 Vaccines, Synthetic 7 Platinum 7 Papillomavirus Vaccines 7 Radiation 6 1,2-diaminocyclohexaneplatinum II citrate 6 Chemotherapy, Adjuvant 5 Bevacizumab 5 pembrolizumab 4 Vinorelbine 4 Pemetrexed 4 Neoadjuvant Therapy 4 Drug Therapy 4 Taxes 3 Radiotherapy, Intensity-Modulated 3 Ondansetron 3 Irinotecan 3 Dexamethasone 3 Chemoradiotherapy 3 tisotumab vedotin 2 specific substance maruyama 2 nimotuzumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04989647 2023-09-07

CERVANTES

The Central and Eastern European Gynecologic Oncology Group

Phase 3 Recruiting

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡